Light-and-enzyme-activated drugs may selectively kill senescent cancer cells
Researchers designed experimental drugs that require two triggers—near-ultraviolet light and the enzyme beta-galactosidase—to become active. This sequential lock-and-key approach was intended to improve selectivity for senescent cancer cells, which can release inflammatory signals and help tumors resist treatment. Laboratory tests showed the combination killed cancer cells more selectively, according to the study in Advanced Science.
Senescence can follow chemotherapy: cells stop dividing yet persist and emit inflammatory cues that may aid tumor treatment resistance. The enzyme beta-galactosidase is a common senescence marker, but it is not exclusive to senescent cells, so relying on it alone risks off-target activation.
The experimental strategy adds near-ultraviolet light as a first switch. Light removes a molecular block, letting beta-galactosidase strip a sugar-based cover and release the drug. In breast cancer cells, light-activated LS-D, derived from doxorubicin, was about eightfold less potent against nonsenescent cells than senescent ones. Lowering the enzyme reduced killing. Tests did not show healthy tissue protection, and selectivity remained imperfect.
If this dual-trigger approach translates beyond lab models, it could influence how clinicians think about lingering senescent cancer cells after treatment. Patients whose tumors resist therapy might eventually benefit from more selective clearance of these cells, potentially reducing collateral damage. However, because current evidence comes from cancer cell comparisons, not healthy tissue, any societal benefit remains uncertain. Researchers, drug developers, and regulators may need further safety and efficacy data before such therapies reach clinical use.